Market Spotlight:  Meningococcal Vaccines Disease 

DISEASE OVERVIEW

Meningitis is an infection of the meninges, the membranes surrounding the brain and spinal cord. It can be caused by a number of different viral and bacterial pathogens including Haemophilus influenzae b (Hib) and Streptococcus pneumoniae. However, in the US, Neisseria meningitidis is the most common cause of bacterial meningitis in infants and young children, as well as one of the most important causes in adults. There are 13 known serotypes of meningococcal disease, of which five (A, B, C, Y, and W-135) account for 90% of the global disease burden.

MARKET SNAPSHOT

Continued uptake of MenB vaccines and GlaxoSmithKline's pentavalent vaccine launch from 2021 will drive market growth.

Cost-effectiveness concerns and scarcity of real-world effectiveness data are key resistors of uptake for MenB vaccines.

Pipeline vaccines with broader serotype protection and novel approaches are positioned to replace marketed products.

Exclusive Sample Report @ https://www.reportsworldwide.com/enquiry?report_id=42613  

Major TOC Market:

  FORECAST: MENINGOCOCCAL VACCINES (Published on 15 November 2017)
  EXECUTIVE SUMMARY
  MARKET OVERVIEW AND TRENDS
  MARKET DEFINITION
  US MARKET FORECAST
  FRANCE MARKET FORECAST
  GERMANY MARKET FORECAST
  ITALY MARKET FORECAST
  SPAIN MARKET FORECAST
  UK MARKET FORECAST
  KEY OPINION LEADER RESEARCH

  MARKETED DRUGS: MENINGOCOCCAL VACCINES (Published on 15 November 2017)
  EXECUTIVE SUMMARY
  PRODUCT OVERVIEW
  PRODUCT PROFILE: BEXSERO
  PRODUCT PROFILE: MENACTRA
  PRODUCT PROFILE: MENVEO
  PRODUCT PROFILE: NIMENRIX
  PRODUCT PROFILE: TRUMENBA

  PIPELINE: MENINGOCOCCAL VACCINES (Published on 15 November 2017)
  EXECUTIVE SUMMARY
  CLINICAL PIPELINE OVERVIEW
  PRODUCT PROFILE (LATE STAGE): MEN QUAD TT
  PRODUCT PROFILE (LATE STAGE): MENABCW-135Y

LIST OF FIGURES
  Figure 1: Meningococcal vaccines market value across the US and five major EU markets, by country, 2016–25
  Figure 2: Total sales of meningococcal vaccines in the US, by risk group, 2016–25
  Figure 3: Total sales of MenB vaccines across the US and five major EU markets, by country, 2016–
  Figure 4: Total sales of meningococcal vaccines across the US and five major EU markets, by class, 2016–25
  Figure 5: Patient-based forecasting methodology for meningococcal vaccines
  Figure 6: Price sources and calculations in the EU, by country
  Figure 7: Total sales of meningococcal vaccines in the US, by risk group, 2016–25
  Figure 8: Total sales of meningococcal vaccines in the US, by class, 2016–25
  Figure 9: Meningococcal vaccination coverage in the US, by risk group, 2016–25
  Figure 10: Total sales of meningococcal vaccines in France, by class, 2016–25
  Figure 11: Meningococcal vaccination coverage in France, by risk group, 2016–25
  Figure 12: Total sales of meningococcal vaccines in Germany, by class, 2016–25
  Figure 13: Meningococcal vaccination coverage in Germany, by risk group, 2016–25
  Figure 14: Total sales of meningococcal vaccines in Italy, by class, 2016–25
  Figure 15: Meningococcal vaccination coverage in Italy, by risk group, 2016–25
  Figure 16: Total sales of meningococcal vaccines in Spain, by class, 2016–25
  Figure 17: Meningococcal vaccination coverage in Spain, by risk group, 2016–25
  Figure 18: Total sales of meningococcal vaccines in the UK, by class, 2016–25
  Figure 19: Meningococcal vaccination coverage in the UK, by risk group, 2016–25
  Figure 20: Bexsero for meningococcal disease – SWOT analysis
  Figure 21: Menactra for meningococcal disease – SWOT analysis
  Figure 22: Menveo for meningococcal disease – SWOT analysis
  Figure 23: Nimenrix for meningococcal disease – SWOT analysis
  Figure 24: Trumenba for meningococcal disease – SWOT analysis
  Figure 25: Men Quad TT for meningococcal vaccination – SWOT analysis
  Figure 26: MenABCW-135Y for meningococcal vaccination – SWOT analysis

LIST OF TABLES
  Table 1: Meningococcal vaccines market value across the US and five major EU markets, by country ($m), 2016–25
  Table 2: Total sales of meningococcal vaccines in the US, by risk group ($m), 2016–25
  Table 3: Total sales of MenB vaccines across the US and five major EU markets, by country ($m), 2016–25
  Table 4: Total sales of meningococcal vaccines across the US and five major EU markets, by class ($m), 2016–25
  Table 5: Recommendations for meningococcal vaccination by national authorities, 2017
  Table 6: Total sales of meningococcal vaccines in the US, by risk group ($m), 2016–25
  Table 7: Total sales of meningococcal vaccines in the US, by class ($m), 2016–25
  Table 8: US meningococcal vaccines market forecast, 2016–25
  Table 9: US meningococcal vaccination coverage rates in recommended risk groups, 2016–25
  Table 10: Total sales of meningococcal vaccines in France, by class ($m), 2016–25
  Table 11: France meningococcal vaccines market forecast, 2016–25
  Table 12: France meningococcal vaccination coverage rates in recommended risk groups, 2016–25
  Table 13: Total sales of meningococcal vaccines in Germany, by class ($m), 2016–25
  Table 14: Germany meningococcal vaccines market forecast, 2016–25
  Table 15: Germany meningococcal vaccination coverage rates in recommended risk groups, 2016–25
  Table 16: Total sales of meningococcal vaccines in Italy, by class ($m), 2016–25
  Table 17: Italy meningococcal vaccines market forecast, 2016–25
  Table 18: Italy meningococcal vaccination coverage rates in recommended risk groups, 2016–25
  Table 19: Total sales of meningococcal vaccines in Spain, by class ($m), 2016–25
  Table 20: Spain meningococcal vaccines market forecast, 2016–25
  Table 21: Spain meningococcal vaccination coverage rates in recommended risk groups, 2016–25
  Table 22: Total sales of meningococcal vaccines in the UK, by class ($m), 2016–25
  Table 23: UK meningococcal vaccines market forecast, 2016–25
  Table 24: UK meningococcal vaccination coverage rates in recommended risk groups, 2016–25
  Table 25: Key marketed vaccines for meningococcal disease
  Table 26: Bexsero drug profile
    Table 27: Bexsero pivotal trial data in meningococcal vaccination
  Table 28: Bexsero late-phase trial data in meningococcal vaccination
  Table 29: Bexsero ongoing late-phase trials in meningococcal vaccination
  Table 30: Menactra drug profile
  Table 31: Menactra pivotal trial data in meningococcal vaccination
  Table 32: Menveo drug profile
  Table 33: Menveo pivotal trial data in meningococcal vaccination
  Table 34: Menveo pivotal trial data in meningococcal vaccination
  Table 35: Menveo ongoing late-phase trials in meningococcal vaccination
  Table 36: Nimenrix drug profile
  Table 37: Nimenrix pivotal trial data in meningococcal vaccination
  Table 38: Nimenrix ongoing late-phase trials in meningococcal vaccination
  Table 39: Trumenba pivotal trial data in meningococcal vaccination
  Table 40: Trumenba late-phase trial data in meningococcal vaccination
  Table 41: Trumenba ongoing trial data in meningococcal vaccination
  Table 42: Phase III pipeline products in development for meningococcal vaccination
  Table 43: Men Quad TT drug profile
  Table 44: Men Quad TT Phase III trials in meningococcal vaccination
  Table 45: Men Quad TT completed Phase II studies in meningococcal vaccination
  Table 46: MenABCW-135Y drug profile
  Table 47: MenABCW-135Y Phase II data in meningococcal vaccination
  Table 48: MenABCW-135Y ongoing trial data in meningococcal vaccination

Table 6: Forecasted global sales, by drug ($m), 2017–22

Ask to Expertise @ https://www.reportsworldwide.com/enquiry?report_id=42613

About US:

Reportsworldwide.com is a one stop shop for all market intelligence needs. Our database of market research reports provides in depth coverage of 12 top industry verticals worldwide. We help you meet your market intelligence needs by mapping it with our database of market research reports including.

Contact Us:

Email: sales@reportsworldwide.com

Phone: +1 (617) 398-1947